Literature DB >> 33597568

Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study.

Norie Saito1,2, Masato Furuhashi3, Masayuki Koyama1,4, Yukimura Higashiura1, Hiroshi Akasaka5, Marenao Tanaka1, Norihito Moniwa1, Hirofumi Ohnishi1,4, Shigeyuki Saitoh1,6, Nobuyuki Ura7, Kazuaki Shimamoto8, Tetsuji Miura1.   

Abstract

Fatty acid-binding protein 4 (FABP4) is secreted from adipose tissue and acts as an adipokine, and an elevated circulating FABP4 level is associated with metabolic disorders and atherosclerosis. However, little is known about the causal link between circulating FABP4 level and mortality in a general population. We investigated the relationship between FABP4 concentration and mortality including cardiovascular death during a 12-year period in subjects of the Tanno-Sobetsu Study, a population-based cohort (n = 721, male/female: 302/419). FABP4 concentration at baseline was significantly higher in female subjects than in male subjects. All-cause death occurred in 123 (male/female: 74/49) subjects, and 34 (male/female: 20/14) and 42 (male/female: 26/16) subjects died of cardiovascular events and cancer, respectively. When divided into 3 groups according to tertiles of FABP4 level at baseline by sex (T1-T3), Kaplan-Meier survival curves showed that there were significant differences in rates of all-cause death and cardiovascular death, but not cancer death, among the groups. Multivariable Cox proportional hazard model analysis with a restricted cubic spline showed that hazard ratio (HR) for cardiovascular death, but not that for all-cause death, significantly increased with a higher FABP4 level at baseline after adjustment of age and sex. The risk of cardiovascular death after adjustment of age, sex, body mass index and levels of brain natriuretic peptide and high-sensitivity C-reactive protein in the 3rd tertile (T3) group (HR: 4.96, 95% confidence interval: 1.20-22.3) was significantly higher than that in the 1st tertile (T1) group as the reference. In conclusion, elevated circulating FABP4 concentration predicts cardiovascular death in a general population.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33597568      PMCID: PMC7889640          DOI: 10.1038/s41598-021-83494-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  57 in total

Review 1.  Inflammatory mechanisms in obesity.

Authors:  Margaret F Gregor; Gökhan S Hotamisligil
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

2.  Increased oxidative stress in obesity and its impact on metabolic syndrome.

Authors:  Shigetada Furukawa; Takuya Fujita; Michio Shimabukuro; Masanori Iwaki; Yukio Yamada; Yoshimitsu Nakajima; Osamu Nakayama; Makoto Makishima; Morihiro Matsuda; Iichiro Shimomura
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

3.  Plasma Levels of Fatty Acid-Binding Protein 4, Retinol-Binding Protein 4, High-Molecular-Weight Adiponectin, and Cardiovascular Mortality Among Men With Type 2 Diabetes: A 22-Year Prospective Study.

Authors:  Gang Liu; Ming Ding; Stephanie E Chiuve; Eric B Rimm; Paul W Franks; James B Meigs; Frank B Hu; Qi Sun
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-09-08       Impact factor: 8.311

4.  Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome.

Authors:  Aimin Xu; Yu Wang; Jian Yu Xu; David Stejskal; Sidney Tam; Jialiang Zhang; Nelson M S Wat; Wai Keung Wong; Karen S L Lam
Journal:  Clin Chem       Date:  2006-01-19       Impact factor: 8.327

5.  Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients.

Authors:  A Cabré; I Lázaro; J Girona; J M Manzanares; F Marimón; N Plana; M Heras; L Masana
Journal:  Atherosclerosis       Date:  2007-06-05       Impact factor: 5.162

6.  Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.

Authors:  M Furkan Burak; Karen E Inouye; Ariel White; Alexandra Lee; Gurol Tuncman; Ediz S Calay; Motohiro Sekiya; Amir Tirosh; Kosei Eguchi; Gabriel Birrane; Daniel Lightwood; Louise Howells; Geofrey Odede; Hanna Hailu; Shauna West; Rachel Garlish; Helen Neale; Carl Doyle; Adrian Moore; Gökhan S Hotamisligil
Journal:  Sci Transl Med       Date:  2015-12-23       Impact factor: 17.956

7.  Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease.

Authors:  Masato Furuhashi; Shutaro Ishimura; Hideki Ota; Manabu Hayashi; Takahiro Nishitani; Marenao Tanaka; Hideaki Yoshida; Kazuaki Shimamoto; Gökhan S Hotamisligil; Tetsuji Miura
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

8.  Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor.

Authors:  Masato Furuhashi; Megumi Matsumoto; Shinya Hiramitsu; Akina Omori; Marenao Tanaka; Norihito Moniwa; Hideaki Yoshida; Junnichi Ishii; Tetsuji Miura
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

9.  Glucose is preferentially utilized for biomass synthesis in pressure-overloaded hearts: evidence from fatty acid-binding protein-4 and -5 knockout mice.

Authors:  Yogi Umbarawan; Mas Rizky A A Syamsunarno; Norimichi Koitabashi; Aiko Yamaguchi; Hirofumi Hanaoka; Takako Hishiki; Yoshiko Nagahata-Naito; Hideru Obinata; Motoaki Sano; Hiroaki Sunaga; Hiroki Matsui; Yoshito Tsushima; Makoto Suematsu; Masahiko Kurabayashi; Tatsuya Iso
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

10.  Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.

Authors:  Masato Furuhashi; Ichiro Sakuma; Takeshi Morimoto; Yukimura Higashiura; Akiko Sakai; Megumi Matsumoto; Mio Sakuma; Michio Shimabukuro; Takashi Nomiyama; Osamu Arasaki; Koichi Node; Shinichiro Ueda
Journal:  Cardiovasc Diabetol       Date:  2020-06-15       Impact factor: 9.951

View more
  5 in total

1.  High fibrosis-4 index predicts the new onset of ischaemic heart disease during a 10-year period in a general population.

Authors:  Yukimura Higashiura; Marenao Tanaka; Kazuma Mori; Takuma Mikami; Itaru Hosaka; Hirofumi Ohnishi; Nagisa Hanawa; Masato Furuhashi
Journal:  Eur Heart J Open       Date:  2022-04-16

2.  Novel Bacillus ginsengihumi CMRO6 Inhibits Adipogenesis via p38MAPK/Erk44/42 and Stimulates Glucose Uptake in 3T3-L1 Pre-Adipocytes through Akt/AS160 Signaling.

Authors:  Kyung Dong Lee; Soundharrajan Ilavenil; Muthusamy Karnan; Chul-Ju Yang; Dahye Kim; Ki Choon Choi
Journal:  Int J Mol Sci       Date:  2022-04-25       Impact factor: 6.208

3.  The Effect of Mineralocorticoid Receptor 3 Antagonists on Anti-Inflammatory and Anti-Fatty Acid Transport Profile in Patients with Heart Failure.

Authors:  Xiaoran Fu; Cristina Almenglo; Ángel Luis Fernandez; José Manuel Martínez-Cereijo; Diego Iglesias-Alvarez; Darío Duran-Muñoz; Tomás García-Caballero; Jose Ramón Gonzalez-Juanatey; Moises Rodriguez-Mañero; Sonia Eiras
Journal:  Cells       Date:  2022-04-08       Impact factor: 7.666

4.  Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals.

Authors:  Marenao Tanaka; Satoko Takahashi; Yukimura Higashiura; Akiko Sakai; Masayuki Koyama; Shigeyuki Saitoh; Kazuaki Shimamoto; Hirofumi Ohnishi; Masato Furuhashi
Journal:  J Diabetes Investig       Date:  2022-01-03       Impact factor: 3.681

5.  Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus.

Authors:  Abid Shaheer; Ashok Kumar; Palat Menon; Mahir Jallo; Shaikh Basha
Journal:  J Clin Med Res       Date:  2021-06-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.